centessa pharmaceuticals plc is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. the company applies an asset-centric r&d model at scale to advance a portfolio of highly validated programs led by industry leading teams. each program is developed by a centessa subsidiary and supported by a centralized infrastructure and the centessa management team. the company is headquartered in cambridge, mass.
Company profile
Ticker
CNTA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Centessa Pharmaceuticals Ltd
SEC CIK
Corporate docs
Subsidiaries
Centessa Pharmaceuticals (UK) Limited • ApcinteX Limited • Z Factor Limited • Morphogen-IX Limited • Capella Bioscience Ltd • LockBody Therapeutics Ltd • Orexia Therapeutics Limited • Centessa Pharmaceuticals Holdings Inc. • Centessa Biosciences, Inc. • Centessa Pharmaceuticals, LLC. ...
CNTA stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
25 Jun 24
8-K
Departure of Directors or Certain Officers
10 Jun 24
DEFA14A
Additional proxy soliciting materials
20 May 24
10-Q
2024 Q1
Quarterly report
13 May 24
8-K
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for Anticipated Upcoming Program Milestones
13 May 24
ARS
2023 FY
Annual report to shareholders
9 May 24
DEF 14A
Definitive proxy
9 May 24
PRE 14A
Preliminary proxy
26 Apr 24
424B5
Prospectus supplement for primary offering
24 Apr 24
8-K
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
24 Apr 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 118.22 mm | 118.22 mm | 118.22 mm | 118.22 mm | 118.22 mm | 118.22 mm |
Cash burn (monthly) | 3.27 mm | 11.81 mm | 12.52 mm | 13.64 mm | 12.43 mm | 12.48 mm |
Cash used (since last report) | 12.65 mm | 45.68 mm | 48.41 mm | 52.73 mm | 48.05 mm | 48.26 mm |
Cash remaining | 105.57 mm | 72.54 mm | 69.81 mm | 65.49 mm | 70.17 mm | 69.96 mm |
Runway (months of cash) | 32.3 | 6.1 | 5.6 | 4.8 | 5.6 | 5.6 |
Institutional ownership, Q1 2024
71.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 3 |
Closed positions | 26 |
Increased positions | 3 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 280.92 bn |
Total shares | 71.35 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Medicxi Growth I | 19.96 mm | $0.00 |
Medicxi Ventures Management | 19.96 mm | $225.58 bn |
Index Ventures Life Vi | 9.96 mm | $112.17 mm |
Atlantic Cooperatief U.A. General | 9.68 mm | $243.11 mm |
Biotechnology Value Fund L P | 6.89 mm | $21.92 mm |
Vida Ventures Advisors | 3.93 mm | $44.43 bn |
Tanager Wealth Management | 696.10 k | $7.87 bn |
TD Asset Management | 228.64 k | $2.58 bn |
Gsa Capital Partners | 13.59 k | $154.00 k |
China Universal Asset Management | 10.82 k | $122.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jul 24 | Crowley John J | Share Option Ordinary Shares | Grant | Acquire A | No | No | 8.8 | 600,000 | 5.28 mm | 600,000 |
30 Jun 24 | Saurabh Saha | Ordinary Shares | Payment of exercise | Dispose F | No | No | 9.03 | 36,263 | 327.45 k | 831,924 |
30 Jun 24 | Tia L Bush | Ordinary Shares | Payment of exercise | Dispose F | No | No | 9.03 | 6,419 | 57.96 k | 163,645 |
30 Jun 24 | David M Chao | Ordinary Shares | Payment of exercise | Dispose F | No | No | 9.03 | 10,385 | 93.78 k | 262,601 |
30 Jun 24 | Iqbal J Hussain | Ordinary Shares | Payment of exercise | Dispose F | No | No | 9.03 | 7,520 | 67.91 k | 205,010 |
Press releases
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
10 Jun 24
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
21 May 24
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
13 May 24